Emilia M Sordillo, MD, PhD

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:35

Article:90

Review Article:7

Comment/Debate:9

Letter:15

Editorial:2

Chapter:3

Recent Artifacts

• Development and characterization of a new monoclonal antibody against SARS-CoV-2 NSP12 (RdRp)
• Evaluation and validation of an RT-PCR assay for specific detection of monkeypox virus (MPXV)
• tRNA abundance, modification and fragmentation in nasopharyngeal swabs as biomarkers for COVID-19 severity
• Tele-entomology and tele-parasitology: A citizen science-based approach for surveillance and control of Chagas disease in Venezuela
• Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants
• Cutaneous leishmaniosis due to Leishmania mexicana in a cat treated with cryotherapy
• A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants
• Murine Broadly Reactive Antineuraminidase Monoclonal Antibodies Protect Mice from Recent Influenza B Virus Isolates and Partially Inhibit Virus Transmission in the Guinea Pig Model
• Pan-stage real-time PCR for quantitation of Trypanosoma cruzi parasitic loads in blood samples
• Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Sordillo during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.